BSTC BioSpecifics Technologies Corp

54.50
0  0%
Previous Close 54.68
Open 54.64
Price To book 6.95
Market Cap 390.33M
Shares 7,162,000
Volume 29,185
Short Ratio 5.08
Av. Daily Volume 28,494

SEC filingsSee all SEC filings

  1. 8-K - Current report 17773215
  2. 8-K - Current report 17766637
  3. 8-K - Current report 17744702
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17694671
  5. 8-K - Current report 17692181

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Endo is currently performing a commercial assessment.
XIAFLEX
Plantar fibromatosis
Phase 2 topline data released June 2016 - endpoints met
XIAFLEX
Human lipomas
Phase 2b data released November 17, 2016. Met endpoints. Phase 3 planned for 2H 2017.
XIAFLEX
Edematous fibrosclerotic panniculopathy (“cellulite”)
Phase 2b trial did not meet endpoint. Endo is currently performing a commercial assessment.
XIAFLEX
Adhesive Capsulitis (“Frozen Shoulder syndrome”)

Latest News

  1. Biospecifics Technologies Corp. – Value Analysis (NASDAQ:BSTC) : April 21, 2017
  2. Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : April 20, 2017
  3. BioSpecifics Technologies Corp. Initiates Phase 1 Clinical Trial of XIAFLEX for Treatment of Uterine Fibroids
  4. ETFs with exposure to Biospecifics Technologies Corp. : April 7, 2017
  5. Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : April 7, 2017
  6. BioSpecifics Technologies Corp. to Present at the 16th Annual Needham Healthcare Conference
  7. Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : March 24, 2017
  8. Biospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  9. BioSpecifics posts 4Q profit
  10. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2016 Financial Results
  11. Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : March 13, 2017
  12. Biotechs Among 5 Stocks Setting Up for Major Breakouts
  13. Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : January 31, 2017
  14. BioSpecifics Technologies Corp. to Present at NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference
  15. Biospecifics Technologies Corp. – Value Analysis (NASDAQ:BSTC) : January 19, 2017
  16. The Life Sciences Report Announces 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
  17. Is BioSpecifics Technologies Corp. (BSTC) A Good Stock To Buy Right Now?
  18. BioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of CCH in Patients with Cellulite
  19. BioSpecifics Technologies Corp. Reports Third Quarter 2016 Financial Results

SEC Filings

  1. 8-K - Current report 17773215
  2. 8-K - Current report 17766637
  3. 8-K - Current report 17744702
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17694671
  5. 8-K - Current report 17692181
  6. 8-K - Current report 17668660
  7. 8-K - Current report 17611901
  8. SC 13G - Statement of acquisition of beneficial ownership by individuals 17555934
  9. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17544763
  10. 8-K - Current report 17512260